{
    "nct_id": "NCT05531656",
    "title": "Synaptic Therapy Alzheimer's Research Trial (START): A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease Over 18 Months.",
    "status": "ACTIVE_NOT_RECRUITING",
    "last_update_time": "2025-09-16",
    "description_brief": "This is a multicenter randomized, double-blind, placebo-controlled Phase 2 study designed to evaluate the efficacy, safety, and tolerability of two doses of CT1812 compared to placebo in participants diagnosed with early Alzheimer's disease.",
    "description_detailed": "This is a multicenter randomized, double-blind, placebo-controlled Phase 2 study designed to evaluate the efficacy, safety, and tolerability of two doses of CT1812 compared to placebo for approximately 18 months (72 weeks) in approximately 540 participants diagnosed with early Alzheimer's disease\n\nParticipants will be randomized 1:1:1 to receive either 100mg or 200mg of CT1812 or placebo. CT1812 or placebo will be administered as 2 capsules to be taken orally once daily.",
    "phase": [
        "PHASE2"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": null,
    "target_category": "disease-targeted small molecule",
    "drug": [
        "CT1812"
    ],
    "placebo": [
        "placebo"
    ],
    "explanation_target": [
        "Reason: The investigational agent CT1812 is a brain-penetrant small molecule that binds the sigma-2 (\u03c3-2) receptor complex and displaces toxic amyloid-\u03b2 (A\u03b2) oligomers from neuronal/synaptic binding sites \u2014 i.e., it targets an AD pathological mechanism rather than being a biologic or a general symptomatic/cognitive enhancer. \ue200cite\ue202turn0search1\ue202turn0search2\ue201",
        "Act: The provided trial description (START / NCT05531656) is a randomized, double\u2011blind, placebo\u2011controlled Phase 2 study of CT1812 in early Alzheimer\u2019s disease over ~18 months, confirming the intervention is CT1812 (oral) with placebo control. Based on the mechanism (\u03c3\u20112 receptor ligand that displaces A\u03b2 oligomers) CT1812 fits the definition of a disease\u2011targeted small molecule. \ue200cite\ue202turn0search0\ue202turn0search7\ue201",
        "Web-search support / key sources: - Phase 1/2 and mechanistic publications describing CT1812 as a sigma\u20112 receptor ligand that displaces A\u03b2 oligomers and has been tested for synaptic biomarker effects. \ue200cite\ue202turn0search1\ue202turn0search3\ue201 - Company / press and summary sources describing target engagement (A\u03b2 oligomer displacement) and development status. \ue200cite\ue202turn0search2\ue202turn0search6\ue201 - Clinical trial registry entry for the START Phase 2 trial describing CT1812 vs placebo in early AD. \ue200cite\ue202turn0search0\ue201",
        "Reflect: Classification check \u2014 CT1812 is not a monoclonal antibody or vaccine (so not a 'disease\u2011targeted biologic'), it is described in the literature and company materials as a small\u2011molecule \u03c3\u20112 receptor ligand that modulates A\u03b2 oligomer binding (a disease\u2011pathology mechanism). It is therefore best classified as 'disease\u2011targeted small molecule'. No substantive information in the trial description suggests the drug is solely a symptomatic cognitive enhancer or an agent for neuropsychiatric symptom management. \ue200cite\ue202turn0search1\ue202turn0search2\ue202turn0search6\ue201"
    ],
    "agent_type": "A) Amyloid beta",
    "explanation_agent": [
        "Reason: CT1812 is a brain\u2011penetrant, disease\u2011targeted small molecule that binds the sigma\u20112 (S2R) receptor complex and allosterically displaces toxic amyloid\u2011\u03b2 (A\u03b2) oligomers from neuronal/synaptic binding sites \u2014 the intervention explicitly acts on an amyloid\u2011related pathological mechanism rather than being purely symptomatic. \ue200cite\ue202turn0search1\ue202turn0search2\ue201",
        "Act: The START trial (Synaptic Therapy Alzheimer's Research Trial, NCT05531656) is a randomized, double\u2011blind, placebo\u2011controlled Phase 2 study of oral CT1812 in early AD, confirming the drug intervention and trial intent. Based on the mechanism (\u03c3\u20112 receptor ligand that displaces A\u03b2 oligomers) the most specific CADRO match is A) Amyloid beta. \ue200cite\ue202turn1search0\ue202turn1search3\ue201",
        "Reflect: CT1812\u2019s primary hypothesized disease\u2011modifying action is displacement/clearance of A\u03b2 oligomers from synapses (supported by preclinical and clinical biomarker studies), so classifying it under CADRO A) Amyloid beta best captures the drug\u2019s biological focus. It is a small molecule modulator of a receptor complex that impacts amyloid oligomer binding \u2014 not a biologic, nor a purely symptomatic agent \u2014 so R) Multi\u2011target or other categories are less specific here. \ue200cite\ue202turn0search0\ue202turn0search4\ue201",
        "Web-search key sources (selected): Preclinical/clinical biomarker study describing CT1812 mechanism and A\u03b2 oligomer displacement (Alzheimer's & Dementia / PubMed). \ue200cite\ue202turn0search0\ue202turn0search1\ue201",
        "Clinical trial registry and study pages for START (NCT05531656) confirming trial design, CT1812 intervention, and dosing plan. \ue200cite\ue202turn1search0\ue202turn1search2\ue201"
    ]
}